Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Factor Xa Inhibitors"" wg kryterium: Temat


Tytuł :
Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
Autorzy :
Milentijevic D; Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, United States. Electronic address: .
Lin JH; Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, United States.
Connolly N; Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, United States.
Chen YW; Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, United States.
Kogan E; Janssen Research & Development, LLC, Raritan, NJ, United States.
Shrivastava S; Mu Sigma Business Solutions Pvt. Ltd., Bengaluru, India.
Sjoeland E; Janssen Research & Development, LLC, Raritan, NJ, United States.
Alberts MJ; Hartford HealthCare, Hartford, CT, United States.
Pokaż więcej
Źródło :
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2021 May; Vol. 30 (5), pp. 105715. Date of Electronic Publication: 2021 Mar 17.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Anticoagulants/*therapeutic use
Atrial Fibrillation/*drug therapy
Factor Xa Inhibitors/*therapeutic use
Rivaroxaban/*therapeutic use
Stroke/*prevention & control
Warfarin/*therapeutic use
Aged ; Aged, 80 and over ; Anticoagulants/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/epidemiology ; Databases, Factual ; Factor Xa Inhibitors/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Rivaroxaban/adverse effects ; Severity of Illness Index ; Stroke/diagnosis ; Stroke/epidemiology ; Time Factors ; Treatment Outcome ; United States/epidemiology ; Warfarin/adverse effects
Czasopismo naukowe
Tytuł :
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Autorzy :
Capell WH; CPC Clinical Research, Aurora, CO; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: .
Barnathan ES; Janssen Research and Development LLC, Raritan, NJ.
Piazza G; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Spyropoulos AC; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Huntington, NY; Institute for Health Innovation and Outcomes Research, Feinstein Institutes for Medical Research, Manhasset, NY; Department of Medicine, Northwell Health at Lenox Hill Hospital, New York, NY.
Hsia J; CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Bull S; Janssen Research and Development LLC, Raritan, NJ.
Lipardi C; Janssen Research and Development LLC, Raritan, NJ.
Sugarmann C; Janssen Research and Development LLC, Raritan, NJ.
Suh E; Janssen Research and Development LLC, Raritan, NJ.
Rao JP; REDCap Cloud, Encinitas, CA.
Hiatt WR; CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Bonaca MP; CPC Clinical Research, Aurora, CO; Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Pokaż więcej
Źródło :
American heart journal [Am Heart J] 2021 May; Vol. 235, pp. 12-23. Date of Electronic Publication: 2021 Feb 09.
Typ publikacji :
Clinical Trial Protocol; Clinical Trial, Phase III; Journal Article; Multicenter Study; Pragmatic Clinical Trial
MeSH Terms :
Hospitalization*
Outpatients*
COVID-19/*complications
Factor Xa Inhibitors/*therapeutic use
Rivaroxaban/*therapeutic use
Thrombosis/*prevention & control
Adult ; COVID-19/mortality ; Cause of Death ; Double-Blind Method ; Extremities/blood supply ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Hemorrhage/mortality ; Hospital Mortality ; Humans ; Ischemia/etiology ; Ischemic Stroke/etiology ; Male ; Middle Aged ; Myocardial Infarction/etiology ; Placebos/therapeutic use ; Rivaroxaban/adverse effects ; Thrombosis/mortality ; Venous Thromboembolism/mortality ; Venous Thromboembolism/prevention & control
Czasopismo naukowe
Tytuł :
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
Autorzy :
Walter E; IPF Institute for Pharmaeconomic Research, Vienna, Austria.
Voit M; IPF Institute for Pharmaeconomic Research, Vienna, Austria.
Eichhober G; IPF Institute for Pharmaeconomic Research, Vienna, Austria.
Pokaż więcej
Źródło :
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2021 Apr; Vol. 21 (2), pp. 265-275. Date of Electronic Publication: 2020 Aug 23.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Atrial Fibrillation/*drug therapy
Factor Xa Inhibitors/*administration & dosage
Pyrazoles/*administration & dosage
Pyridones/*administration & dosage
Stroke/*prevention & control
Aged ; Aged, 80 and over ; Anticoagulants/administration & dosage ; Anticoagulants/economics ; Atrial Fibrillation/complications ; Atrial Fibrillation/economics ; Austria ; Cost-Benefit Analysis ; Factor Xa Inhibitors/economics ; Female ; Humans ; Male ; Middle Aged ; Models, Econometric ; Pyrazoles/economics ; Pyridones/economics ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Stroke/economics ; Stroke/etiology ; Warfarin/administration & dosage ; Warfarin/economics
Czasopismo naukowe
Tytuł :
Mixing Drugs and Genetics: A Complex Hemorrhagic Cocktail.
Autorzy :
Barbolini L; Division of General Internal Medicine, Geneva University Hospitals, Switzerland.
Terrier J; Division of General Internal Medicine, Geneva University Hospitals, Switzerland; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Switzerland; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Switzerland. Electronic address: .
Marti C; Division of General Internal Medicine, Geneva University Hospitals, Switzerland.
Samer C; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Switzerland.
Daali Y; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Switzerland; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Switzerland.
Fontana P; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Switzerland; Division of Angiology and Haemostasis, Geneva University Hospitals, Switzerland.
Reny JL; Division of General Internal Medicine, Geneva University Hospitals, Switzerland; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Switzerland.
Pokaż więcej
Źródło :
The American journal of medicine [Am J Med] 2021 Mar; Vol. 134 (3), pp. e211-e212. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Factor Xa Inhibitors/*pharmacology
Subarachnoid Hemorrhage/*chemically induced
Subarachnoid Hemorrhage/*genetics
ATP Binding Cassette Transporter, Subfamily B/genetics ; Aged, 80 and over ; Drug Interactions ; Factor Xa Inhibitors/therapeutic use ; Female ; Humans ; Polypharmacy
Czasopismo naukowe
Tytuł :
A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis.
Autorzy :
Powell M; UCHealth University of Colorado Hospital, Aurora, CO, USA.
Tremolet de Villers K; UCHealth University of Colorado Hospital, Aurora, CO, USA.
Schwarz K; UCHealth University of Colorado Hospital, Aurora, CO, USA.
Case D; UCHealth University of Colorado Hospital, Aurora, CO, USA.; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Trujillo T; UCHealth University of Colorado Hospital, Aurora, CO, USA.; University of Colorado, Aurora, CO, USA.
Pokaż więcej
Źródło :
The Annals of pharmacotherapy [Ann Pharmacother] 2021 Mar; Vol. 55 (3), pp. 286-293. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors/*therapeutic use
Venous Thromboembolism/*drug therapy
Adult ; Factor Xa Inhibitors/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Comparing Safety and Efficacy of Rivaroxaban with Warfarin for Patients after Successful Stent Placement for Chronic Iliofemoral Occlusion: A Retrospective Single Institution Study.
Autorzy :
Zhang X; Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China; Vascular Centre of Shanghai JiaoTong University, Shanghai, China.
Huang J; Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China; Vascular Centre of Shanghai JiaoTong University, Shanghai, China.
Peng Z; Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China; Vascular Centre of Shanghai JiaoTong University, Shanghai, China.
Lu X; Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China; Vascular Centre of Shanghai JiaoTong University, Shanghai, China.
Yang X; Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China; Vascular Centre of Shanghai JiaoTong University, Shanghai, China.
Ye K; Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China; Vascular Centre of Shanghai JiaoTong University, Shanghai, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery [Eur J Vasc Endovasc Surg] 2021 Mar; Vol. 61 (3), pp. 484-489. Date of Electronic Publication: 2020 Dec 31.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Femoral Vein*/diagnostic imaging
Femoral Vein*/physiopathology
Iliac Vein*/diagnostic imaging
Iliac Vein*/physiopathology
Stents*
Anticoagulants/*therapeutic use
Endovascular Procedures/*instrumentation
Factor Xa Inhibitors/*therapeutic use
Postthrombotic Syndrome/*therapy
Rivaroxaban/*therapeutic use
Warfarin/*therapeutic use
Aged ; Anticoagulants/adverse effects ; Chronic Disease ; Databases, Factual ; Endovascular Procedures/adverse effects ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Middle Aged ; Postthrombotic Syndrome/diagnostic imaging ; Postthrombotic Syndrome/physiopathology ; Registries ; Retrospective Studies ; Rivaroxaban/adverse effects ; Time Factors ; Treatment Outcome ; Vascular Patency ; Warfarin/adverse effects
Czasopismo naukowe
Tytuł :
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Autorzy :
Al-Horani RA; Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA, 70125-1089, USA. .
Pokaż więcej
Źródło :
American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2020 Dec; Vol. 20 (6), pp. 525-533.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19/*drug therapy
COVID-19/*physiopathology
Factor Xa Inhibitors/*pharmacology
Factor Xa Inhibitors/*therapeutic use
Blood Coagulation/drug effects ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/physiopathology ; Cytokines/biosynthesis ; Drug Interactions ; Factor Xa/metabolism ; Factor Xa Inhibitors/adverse effects ; Factor Xa Inhibitors/pharmacokinetics ; Half-Life ; Humans ; Inflammation Mediators/metabolism ; Metabolic Clearance Rate ; Multiple Organ Failure/physiopathology ; Multiple Organ Failure/prevention & control ; Pandemics ; Protein Binding/physiology ; SARS-CoV-2 ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Autorzy :
Guimarães HP; Research Institute - Heart Hospital (HCor), São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo-SP, Brazil. Electronic address: .
de Barros E Silva PGM; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Liporace IL; Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
Sampaio RO; Incor - Instituto do Coração do HCFMUSP, São Paulo, Brazil.
Tarasoutchi F; Incor - Instituto do Coração do HCFMUSP, São Paulo, Brazil.
Paixão M; Incor - Instituto do Coração do HCFMUSP, São Paulo, Brazil.
Hoffmann-Filho CR; Hospital Regional Hans Dieter Schmidt - Joinvile, Brazil.
Patriota R; Hospital Metropolitano Sul Dom Helder Câmara, Cabo de Santo Agostinho, Brazil.
Leiria TLL; Instituto de Cardiologia do Rio Grande do Sul (FUC), Porto Alegre, Brazil.
Lamprea D; Procape, Recife, Brazil.
Precoma DB; Sociedade Hospitalar Angelina Caron, Campina Grande do Sul, Brazil.
Atik FA; Instituto de Cardiologia do Distrito Federal, Brasília, Brazil.
Silveira FS; Clínica do Coração Sergipe - Aracajú, Brazil.
Farias FR; Quanta Diagnóstico e Terapia, Curitiba, Brazil.
Barreto DO; Hospital Evangélico de Vila Velha, Vila Velha, Brazil.
Almeida AP; Unidade Médico Cirúrgica - Unimec, Vitória da Conquista, Brazil.
Zilli AC; Hospital de Caridade São Vicente de Paulo, Jundiaí, Brazil.
de Souza Neto JD; Hospital Messejana, Ceará, Brazil.
Cavalcante MA; Hospital Regional de Presidente Prudente, Presidente Prudente, Brazil.
Figueira FAMS; IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil.
Junior RA; HUPES-Hospital Universitário Prof Edgard Santos, Salvador, Brazil.
Moisés VA; UNIFESP, São Paulo, Brazil.
Mesas CE; Hospital de Universidade Estadual de Londrina, Londrina, Brazil.
Ardito RV; IMC - Instituto de Moléstias Cardiovasculares, São José do Rio Preto, Brazil.
Kalil PSA; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Paiva MSMO; Eurolatino Natal Center, Natal, Brazil.
Maldonado JGA; Serviço de Eletrofisiologia e Marca-Passo do Hospital Universitário Francisca Mendes (HUFM)-Manaus, Brazil.
de Lima CEB; Cardiolima Piauí, Teresina, Brazil.
D'Oliveira Vieira R; Hospital e Clínica São Roque, Ipiaú, Brazil.
Laranjeira L; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Kojima F; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Damiani L; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Nakagawa RH; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Dos Santos JRY; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Sampaio BS; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Campos VB; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Saraiva JFK; Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Fonseca FH; UNIFESP, São Paulo, Brazil; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Pinto IM; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Magalhães CC; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Ferreira JFM; Incor - Instituto do Coração do HCFMUSP, São Paulo, Brazil; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Lopes RD; Duke Clinical Research Institute (DCRI), Durham-NC.
Pavanello R; Research Institute - Heart Hospital (HCor), São Paulo, Brazil; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Cavalcanti AB; Research Institute - Heart Hospital (HCor), São Paulo, Brazil.
Berwanger O; Research Institute - Heart Hospital (HCor), São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo-SP, Brazil; Sociedade de Cardiologia do Estado de São Paulo (SOCESP), Sao Paulo, Brazil.
Pokaż więcej
Corporate Authors :
RIVER (RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial) Investigators
Źródło :
American heart journal [Am Heart J] 2021 Jan; Vol. 231, pp. 128-136. Date of Electronic Publication: 2020 Oct 10.
Typ publikacji :
Clinical Trial Protocol; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Bioprosthesis*/adverse effects
Heart Valve Prosthesis*/adverse effects
Mitral Valve*
Atrial Fibrillation/*complications
Atrial Flutter/*complications
Factor Xa Inhibitors/*therapeutic use
Rivaroxaban/*therapeutic use
Thrombosis/*prevention & control
Administration, Oral ; Aspirin/administration & dosage ; Brazil ; Cause of Death ; Creatinine/metabolism ; Embolism ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/adverse effects ; Hemorrhage/chemically induced ; Hospitalization ; Humans ; Ischemic Attack, Transient ; Rivaroxaban/administration & dosage ; Rivaroxaban/adverse effects ; Sample Size ; Stroke ; Surgical Procedures, Operative ; Thrombosis/etiology ; Treatment Outcome ; Warfarin/administration & dosage ; Warfarin/adverse effects ; Warfarin/therapeutic use
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories.
Autorzy :
Kaplan RM; Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Tanaka Y; Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Passman RS; Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL.; Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Fine M; Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Rasmussen-Torvik LJ; Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Vupputuri S; Kaiser Permanente, Mid-Atlantic Permanente Research Institute Rockville MD.
Martin K; Division of Benign Hematology Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Khan SS; Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine Chicago IL.; Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL.
Pokaż więcej
Źródło :
Journal of the American Heart Association [J Am Heart Assoc] 2020 Dec 15; Vol. 9 (24), pp. e017383. Date of Electronic Publication: 2020 Dec 11.
Typ publikacji :
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Atrial Fibrillation/*drug therapy
Factor Xa Inhibitors/*therapeutic use
Obesity, Morbid/*metabolism
Stroke/*prevention & control
Aged ; Aged, 80 and over ; Atrial Fibrillation/complications ; Atrial Fibrillation/epidemiology ; Body Mass Index ; Embolism/epidemiology ; Factor Xa Inhibitors/pharmacokinetics ; Factor Xa Inhibitors/pharmacology ; Female ; Follow-Up Studies ; Humans ; Intracranial Hemorrhages/epidemiology ; Ischemic Stroke/epidemiology ; Male ; Middle Aged ; Obesity, Morbid/classification ; Obesity, Morbid/epidemiology ; Proportional Hazards Models ; Retrospective Studies ; Safety ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Prothrombin complex use in patients treated with direct-acting oral anticoagulants.
Autorzy :
Martínez de Narvajas Urra I; Servicio de Medicina Interna, Hospital San Pedro, Logroño, La Rioja, España. Electronic address: .
Daroca Pérez R; Servicio de Medicina Interna, Hospital San Pedro, Logroño, La Rioja, España.
Arnedo Hernández S; Servicio de Medicina Interna, Hospital San Pedro, Logroño, La Rioja, España.
Pokaż więcej
Transliterated Title :
Uso de complejo protrombínico en pacientes tratados con anticoagulantes orales de acción directa.
Źródło :
Medicina clinica [Med Clin (Barc)] 2021 Feb 26; Vol. 156 (4), pp. 193-194. Date of Electronic Publication: 2020 Mar 09.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Factor Xa Inhibitors*/therapeutic use
Prothrombin*/therapeutic use
Administration, Oral ; Anticoagulants/adverse effects ; Hemorrhage/drug therapy ; Humans
Raport
Tytuł :
Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report.
Autorzy :
Toyoda J; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Morioka D; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan. .; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. .
Horii N; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Nakayama G; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Oyama N; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Asano F; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Izumisawa Y; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Miura M; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.
Sato Y; Department of Surgery, Yokohama Ekisaikai Hospital, 1-2 Yamadacho, Naka-ku, Yokohama, 231-0036, Japan.
Endo I; Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Pokaż więcej
Źródło :
Journal of medical case reports [J Med Case Rep] 2021 Feb 10; Vol. 15 (1), pp. 52. Date of Electronic Publication: 2021 Feb 10.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Factor Xa Inhibitors*
Portal Vein*/diagnostic imaging
Portal Vein*/pathology
Aged ; Humans ; Liver Cirrhosis/complications ; Male ; Postoperative Period ; Pyridines ; Thiazoles
Czasopismo naukowe
Tytuł :
Acquired Hemophilia A in an Elderly Patient on Apixaban Therapy.
Autorzy :
Skorochod R; Hadassah University Hospital, Hebrew University-Hadassah School of Medicine, Jerusalem, Israel.
Applbaum Y; Department of Radiology, MRI Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Nesher G; Hadassah University Hospital, Hebrew University-Hadassah School of Medicine, Jerusalem, Israel.; Department of Internal Medicine A, Shaare Zedek Medical Center, Jerusalem, Israel.
Tvito A; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Pokaż więcej
Źródło :
The Israel Medical Association journal : IMAJ [Isr Med Assoc J] 2021 Feb; Vol. 23 (2), pp. 130-131.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Factor Xa Inhibitors/*adverse effects
Hemophilia A/*chemically induced
Pyrazoles/*adverse effects
Pyridones/*adverse effects
Aged, 80 and over ; Atrial Fibrillation/drug therapy ; Delayed Diagnosis ; Factor Xa Inhibitors/administration & dosage ; Female ; Hemophilia A/diagnosis ; Humans ; Pyrazoles/administration & dosage ; Pyridones/administration & dosage
Czasopismo naukowe
Tytuł :
Venous thromboembolism in trauma patients with lower limb cast immobilization, associated risk reduction and complication using rivaroxaban.
Autorzy :
Ali IA; Doncaster and Bassetlaw Teaching Hospitals, Kilton Hill, Nottinghamshire, S81 0BD, UK. .; Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Trust, Ashton Road, Lancaster, LA1 0RP, UK. .
Elbana H; Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Trust, Ashton Road, Lancaster, LA1 0RP, UK.
Farhan M; Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Trust, Ashton Road, Lancaster, LA1 0RP, UK.
Qureshi IF; Doncaster and Bassetlaw Teaching Hospitals, Kilton Hill, Nottinghamshire, S81 0BD, UK.
Mubashir A; Doncaster and Bassetlaw Teaching Hospitals, Kilton Hill, Nottinghamshire, S81 0BD, UK.
Pokaż więcej
Źródło :
Irish journal of medical science [Ir J Med Sci] 2021 Feb; Vol. 190 (1), pp. 169-175. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors/*adverse effects
Lower Extremity/*injuries
Rivaroxaban/*adverse effects
Venous Thromboembolism/*etiology
Cohort Studies ; Factor Xa Inhibitors/pharmacology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Risk Factors ; Risk Reduction Behavior ; Rivaroxaban/pharmacology
Czasopismo naukowe
Tytuł :
Investigation of Direct-Acting Oral Anticoagulants and the Incidence of Venous Thromboembolism in Patients Weighing ≥120 kg Compared to Patients Weighing <120 kg.
Autorzy :
Aloi KG; James A. Haley Veterans' Hospital, Tampa, FL, USA.
Fierro JJ; James A. Haley Veterans' Hospital, Tampa, FL, USA.
Stein BJ; James A. Haley Veterans' Hospital, Tampa, FL, USA.
Lynch SM; James A. Haley Veterans' Hospital, Tampa, FL, USA.
Shapiro RJ; James A. Haley Veterans' Hospital, Tampa, FL, USA.
Pokaż więcej
Źródło :
Journal of pharmacy practice [J Pharm Pract] 2021 Feb; Vol. 34 (1), pp. 64-69. Date of Electronic Publication: 2019 Jun 25.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors*/adverse effects
Venous Thromboembolism*/diagnosis
Venous Thromboembolism*/drug therapy
Venous Thromboembolism*/epidemiology
Administration, Oral ; Anticoagulants/adverse effects ; Hemorrhage/drug therapy ; Humans ; Incidence ; Pyridones/adverse effects ; Retrospective Studies ; Rivaroxaban/adverse effects
Czasopismo naukowe
Tytuł :
Insights Into Direct Oral Anticoagulant Therapy Implementation of Stroke Survivors with Atrial Fibrillation in an Ambulatory Setting.
Autorzy :
Albert V; Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Petersplatz 14, Postfach 2148, 4051 Basel, Switzerland, Tel: +41 61 207 14 26. Electronic address: .
Polymeris AA; Department of Neurology and Stroke Centre, University Hospital Basel and University of Basel, Basel, Switzerland, Tel: +41 61 265 44 91. Electronic address: .
Dietrich F; Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Petersplatz 14, Postfach 2148, 4051 Basel, Switzerland, Tel: +41 61 207 14 26. Electronic address: .
Engelter ST; Department of Neurology and Stroke Centre, University Hospital Basel and University of Basel, Basel, Switzerland, Tel: +41 61 265 44 91; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland, Tel: +41 61 326 41 05. Electronic address: .
Hersberger KE; Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Petersplatz 14, Postfach 2148, 4051 Basel, Switzerland, Tel: +41 61 207 14 26. Electronic address: .
Schaedelin S; Clinical Trial Unit, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland, Tel: +41 61 556 51 67. Electronic address: .
Lyrer PA; Department of Neurology and Stroke Centre, University Hospital Basel and University of Basel, Basel, Switzerland, Tel: +41 61 265 44 91. Electronic address: .
Arnet I; Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Petersplatz 14, Postfach 2148, 4051 Basel, Switzerland, Tel: +41 61 207 14 26. Electronic address: .
Pokaż więcej
Źródło :
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2021 Feb; Vol. 30 (2), pp. 105530. Date of Electronic Publication: 2020 Dec 14.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Ambulatory Care*
Medication Adherence*
Atrial Fibrillation/*drug therapy
Factor Xa Inhibitors/*administration & dosage
Ischemic Stroke/*etiology
Aged ; Aged, 80 and over ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Drug Administration Schedule ; Factor Xa Inhibitors/adverse effects ; Female ; Health Knowledge, Attitudes, Practice ; Humans ; Ischemic Stroke/diagnosis ; Male ; Patient Education as Topic ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Autorzy :
Ajmal M; University of Arizona, College of Medicine, Tucson, AZ, USA.
Friedman J; University of Arizona, College of Medicine, Tucson, AZ, USA.
Sipra QUAR; University of Arizona, College of Medicine, Tucson, AZ, USA.
Lassar T; University of Arizona, College of Medicine, Tucson, AZ, USA.
Pokaż więcej
Źródło :
Cardiovascular therapeutics [Cardiovasc Ther] 2021 Jan 08; Vol. 2021, pp. 8886210. Date of Electronic Publication: 2021 Jan 08 (Print Publication: 2021).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cardiovascular Diseases/*drug therapy
Factor Xa Inhibitors/*administration & dosage
Rivaroxaban/*administration & dosage
Cardiovascular Diseases/diagnosis ; Clinical Decision-Making ; Factor Xa Inhibitors/adverse effects ; Hemorrhage/chemically induced ; Humans ; Patient Selection ; Risk Factors ; Rivaroxaban/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs.
Autorzy :
Lynch AM; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Ruterbories LK; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Griffith EH; Department of Statistics, North Carolina State University, Raleigh, North Carolina.
Hanel RM; BluePearl Veterinary Partners, Tampa, Florida.
Stablein AP; Comparative Coagulation Section, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Brooks MB; Comparative Coagulation Section, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Pokaż więcej
Źródło :
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) [J Vet Emerg Crit Care (San Antonio)] 2021 Jan; Vol. 31 (1), pp. 18-24. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Journal Article
MeSH Terms :
Anticoagulants/*pharmacology
Blood Coagulation/*drug effects
Factor Xa Inhibitors/*pharmacology
Rivaroxaban/*pharmacology
Administration, Oral ; Animals ; Anticoagulants/administration & dosage ; Blood Coagulation Tests/veterinary ; Dogs ; Factor Xa Inhibitors/administration & dosage ; Male ; Partial Thromboplastin Time/veterinary ; Point-of-Care Testing ; Prospective Studies ; Prothrombin Time/veterinary ; Reference Values ; Rivaroxaban/administration & dosage ; Thrombelastography/veterinary
Czasopismo naukowe
Tytuł :
The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs.
Autorzy :
Lynch AM; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC.
Ruterbories LK; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC.
Griffith E; Department of Statistics, North Carolina State University, Raleigh, NC.
Hanel RM; BluePearl Veterinary Partners, Tampa, FL.
Stablein AP; Comparative Coagulation Section, College of Veterinary Medicine, Cornell University, Ithaca, NY.
Brooks MB; Comparative Coagulation Section, College of Veterinary Medicine, Cornell University, Ithaca, NY.
Pokaż więcej
Źródło :
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) [J Vet Emerg Crit Care (San Antonio)] 2021 Jan; Vol. 31 (1), pp. 59-65. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Journal Article
MeSH Terms :
Meals*
Anti-Ulcer Agents/*pharmacology
Anticoagulants/*pharmacokinetics
Factor Xa Inhibitors/*pharmacokinetics
Rivaroxaban/*pharmacokinetics
Administration, Oral ; Animals ; Anti-Ulcer Agents/administration & dosage ; Anticoagulants/administration & dosage ; Blood Coagulation Tests/veterinary ; Dogs ; Factor Xa Inhibitors/administration & dosage ; Male ; Prospective Studies ; Reference Values ; Rivaroxaban/administration & dosage
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Nonvitamin K Oral Anticoagulants following Cardiac Valve Replacement.
Autorzy :
Stuart MK; From the Department of Pharmacy Services, Princeton Baptist Medical Center, Birmingham, Alabama, the Department of Pharmacy Services, Vanderbilt Wilson County Hospital, Lebanon, Tennessee, and the Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama.
Blackwell SB; From the Department of Pharmacy Services, Princeton Baptist Medical Center, Birmingham, Alabama, the Department of Pharmacy Services, Vanderbilt Wilson County Hospital, Lebanon, Tennessee, and the Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama.
Holder HB; From the Department of Pharmacy Services, Princeton Baptist Medical Center, Birmingham, Alabama, the Department of Pharmacy Services, Vanderbilt Wilson County Hospital, Lebanon, Tennessee, and the Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama.
Wood EL; From the Department of Pharmacy Services, Princeton Baptist Medical Center, Birmingham, Alabama, the Department of Pharmacy Services, Vanderbilt Wilson County Hospital, Lebanon, Tennessee, and the Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama.
Starr JA; From the Department of Pharmacy Services, Princeton Baptist Medical Center, Birmingham, Alabama, the Department of Pharmacy Services, Vanderbilt Wilson County Hospital, Lebanon, Tennessee, and the Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama.
Pokaż więcej
Źródło :
Southern medical journal [South Med J] 2021 Jan; Vol. 114 (1), pp. 46-50.
Typ publikacji :
Journal Article
MeSH Terms :
Factor Xa Inhibitors/*standards
Heart Valve Prosthesis/*adverse effects
Venous Thromboembolism/*prevention & control
Adolescent ; Adult ; Anticoagulants/pharmacology ; Anticoagulants/therapeutic use ; Factor Xa Inhibitors/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Southeastern United States ; Venous Thromboembolism/drug therapy
Czasopismo naukowe
Tytuł :
Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose.
Autorzy :
Bhagirath VC
Chan N
Hirsh J
Ginsberg J
de Vries TAC
Eikelboom J
Pokaż więcej
Źródło :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2020 Dec 15; Vol. 76 (24), pp. 2906-2907.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor Xa Inhibitors/*blood
Pyrazoles/*blood
Pyridones/*blood
Stroke/*prevention & control
Aged, 80 and over ; Atrial Fibrillation/complications ; Factor Xa Inhibitors/administration & dosage ; Humans ; Pyrazoles/administration & dosage ; Pyridones/administration & dosage ; Stroke/etiology
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies